Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up

BACKGROUND: Nivolumab plus ipilimumab (NIVO+IPI) demonstrated superior efficacy over sunitinib (SUN) for previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214, with a manageable safety profile. We report efficacy and safety with extended follow-up amongst Japanese patients. METH...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Jpn J Clin Oncol
Main Authors: Tomita, Yoshihiko, Kondo, Tsunenori, Kimura, Go, Inoue, Takamitsu, Wakumoto, Yoshiaki, Yao, Masahiro, Sugiyama, Takayuki, Oya, Mototsugu, Fujii, Yasuhisa, Obara, Wataru, Motzer, Robert J, Uemura, Hirotsugu
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6978670/
https://ncbi.nlm.nih.gov/pubmed/31633185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyz132
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados